Tuesday, November 09, 2021 2:44:00 PM
Pfizer and Moderna have brilliantly figured out that the Zelenko Protocol is and has always been the correct approach to treat Covid-19.
Pfizer and Moderna are touting unverified results from their trials of oral repurposed hiv drugs, Paxlovid and molnupiravir, claiming decrease in hospitalization rates of 89% and 50%, respectively.
This is consistent with Dr. Zelenko’s observations since 3/2020, that early prehospital treatment with antiviral medications reduces hospitalization and death by 84%.
Dozens of peer reviewed papers have corroborated Dr. Zelenko’s observations with an average decrease in hospitalization of 85%.
Pfizer and Moderna have still not discovered the clinical benefit of patient risk stratification and use of zinc, which are essential components of the Zelenko Protocol.
Pfizer and Moderna have not commented on the significant side effects of these repurposed hiv drugs.
Another major difference of Pfizer / Moderna drugs versus the Zelenko Protocol is cost. Big pharma drugs will cost $700 a person vs $30 for the Zelenko Protocol.
Perhaps, Pfizer and Moderna are hoping that touting their expensive and unproven drugs will mitigate the horrendous side effects of the covid-19 vaccines https://zstacklife.com/?ref=BestProtocol
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587171/
ANYTHING CAN HAPPEN TO YOUR INVESTMENTS PLEASE DO YOUR DD BEFORE INVESTING AND MAKE $$$$$$$
Recent PFE News
- CVS Health, Starbucks, Shares Weaker; Pinterest Soars • IH Market News • 05/01/2024 01:12:05 PM
- Pfizer Reports First-Quarter 2024 Results • Business Wire • 05/01/2024 10:45:00 AM
- TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer • Business Wire • 04/29/2024 10:40:00 PM
- FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer • Business Wire • 04/29/2024 10:40:00 PM
- Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting • Business Wire • 04/29/2024 10:45:00 AM
- Anglo American Rejects BHP Group’s Offer, Toyota Invests $1.4 Billion in Indiana, and More News • IH Market News • 04/26/2024 11:48:07 AM
- U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B • Business Wire • 04/26/2024 10:45:00 AM
- Pfizer Declares Second-Quarter 2024 Dividend • Business Wire • 04/24/2024 08:37:00 PM
- Coca-Cola and Microsoft Sign Billion-Dollar Agreement, Apple Event Set for May 7, and More News • IH Market News • 04/24/2024 11:28:02 AM
- European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options • Business Wire • 04/22/2024 12:08:00 PM
- Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25 • Business Wire • 04/11/2024 02:00:00 PM
- Delta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More News • IH Market News • 04/10/2024 11:13:48 AM
- Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease • Business Wire • 04/09/2024 10:45:00 AM
- ALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager • PR Newswire (US) • 04/08/2024 04:44:00 PM
- Super Micro Computer and Seagate Shares Surge on Analyst Optimism in Pre-Market Trading, and Latest News • IH Market News • 03/26/2024 11:20:49 AM
- Apple Pre-Market Drop Due to Antitrust Threats, Surprising Profit Boosts Micron Shares, and Latest Market Updates • IH Market News • 03/21/2024 11:17:26 AM
- Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts • Business Wire • 03/20/2024 02:00:00 PM
- Unilever Initiates Ice Cream Division Spin-Off and Announces Job Cuts; Berkshire Ramps Up Share Buyback Efforts, and More • IH Market News • 03/19/2024 11:33:10 AM
- Apple & Google in Talks for Gemini AI on iPhone, Nvidia’s GTC Conference Today, and Latest News • IH Market News • 03/18/2024 11:10:46 AM
- European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease • Business Wire • 03/13/2024 08:00:00 AM
- Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) • Business Wire • 03/12/2024 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 08:55:44 PM
- Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference • Business Wire • 03/05/2024 03:00:00 PM
- Futures Pointing To Continued Weakness On Wall Street • IH Market News • 03/05/2024 02:03:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 06:28:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM